Walleye Capital’s Bicara Therapeutics BCAX Stock Holding History
Bought
Maintained
Sold
Other funds holding BCAX
SL
Walleye Capital's BCAX Position: Q3 2026 in Review
Walleye Capital reduced its Bicara Therapeutics (BCAX) stake by 20% in Q3 2026, selling an estimated $1.78M and leaving 282,138 shares worth $5.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1845.
Walleye Capital first reported a position in BCAX in Q3 2024 and has held it in 5 quarters since. The position peaked at $10.5M in Q2 2026. 167 funds tracked by Wall St. Rank hold BCAX as of Q3 2026.
- Walleye Capital held 282,138 shares of Bicara Therapeutics worth $5.25M as of Q3 2026.
- Walleye Capital sold 71,088 Bicara Therapeutics shares in Q3 2026, an estimated $1.78M.
- Bicara Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #1845 holding.
- Walleye Capital first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 5 quarters since.
- Walleye Capital's Bicara Therapeutics position peaked at $10.5M in Q2 2026.
- 167 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2026.
Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.